Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $1.13M rose 11.6% year over year, behind the +116.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 11.2% from the prior quarter. Over 3 fiscal years it compounded at +31.6% a year.
Context
- Depreciation & amortization amounted to 5.1% of revenue in FY2025, up 2.1 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +11.6% toward the trailing-twelve-month pace of +116.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 4.04M USD
- Year-over-year change
- +252.9%
- 4-year CAGR
- +72.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.04M | +252.9% |
| FY2024 | 2024-12-31 | 1.15M | +27.2% |
| FY2023 | 2023-12-31 | 901K | -49.2% |
| FY2022 | 2022-12-31 | 1.77M | +284.0% |
| FY2021 | 2021-12-31 | 462K | — |
Depreciation & Amortization vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 depreciation & amortization of $4.16M is the 5th highest of the 10 companies compared; the peer median is $2.77M.
- Its year-over-year change of +116.2% is the highest of 10, against a peer median of -1.9%.
- Depreciation & amortization amounts to 4.8% of revenue for ETON, versus a peer median of 2.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $47.58M | -13.0% | +43.1% | 7.3% | |
| LTM Mar 2026 | $34.01M | -4.7% | +24.3% | 5.1% | |
| LTM Sep 2026 | $21.89M | +6.2% | +0.9% | 2.3% | |
| LTM Mar 2026 | $11.75M | -9.8% | -6.6% | 3.2% | |
| LTM Mar 2026 | $4.16M | +116.2% | +31.6% | 4.8% | |
| LTM Mar 2026 | $2.77M | -57.2% | +62.5% | 2.3% | |
| LTM Mar 2026 | $555K | -1.9% | +13.3% | 0.8% | |
| LTM Mar 2026 | $326K | +0.0% | +3.2% | — | |
| LTM Mar 2026 | $103K | +0.0% | -11.6% | 0.2% | |
| LTM Mar 2026 | $43K | +2.4% | +19.8% | — | |
| Peer median (excluding ETON) | $2.77M | -1.9% | +13.3% | 2.3% | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.83M | 21.25M | 31.64M | 39.01M | 79.95M |
| Cost of Revenue | 2.62M | 6.93M | 10.58M | 15.6M | 37.21M |
| Gross Profit | 19.21M | 14.32M | 21.06M | 23.41M | 42.74M |
| Gross Margin | 88.0% | 67.4% | 66.6% | 60.0% | 53.5% |
| Research & Development | 6.24M | 4M | 3.32M | 3.26M | 7.77M |
| Selling, General & Admin | 14.47M | 18.58M | 18.93M | 22.75M | 35.82M |
| Operating Expenses | 20.7M | 22.58M | 22.25M | 26.01M | 42.67M |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| EBITDA | (1.49M) | (7.25M) | 212K | (657K) | 4.27M |
| EBITDA Margin | -6.8% | -34.1% | 0.7% | -1.7% | 5.3% |
| Operating Income | (1.5M) | (8.26M) | (1.19M) | (2.6M) | 72K |
| Operating Margin | -6.8% | -38.9% | -3.8% | -6.7% | 0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.04M | 955K | 1.06M | 2.01M | 4.78M |
| Other Income / Expenses | (460K) | (761K) | 503K | (1.21M) | (4.63M) |
| Income Before Tax | (1.96M) | (9.02M) | (689K) | (3.81M) | (4.56M) |
| Pre-Tax Margin | -9.0% | -42.4% | -2.2% | -9.8% | -5.7% |
| Income Tax Expense | 0 | 0 | 247K | 15K | 43K |
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Net Margin | -9.0% | -42.4% | -3.0% | -9.8% | -5.8% |
| EPS (Basic) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| EPS (Diluted) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| Weighted Avg Shares | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
| Weighted Avg Shares (Diluted) | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.